(29) also proposed a combination of the cell markers CD11b+ CD33+ HLA-DR-CD14+ and CD11b+ CD33+ HLA-DR- CD66b+ as novel severity biomarkers for COVID-19. This evidence concerns the gene CD14 and COVID-19.